



BioRx Expands Therapy Offering to Patients with HAE

September 12, 2011



BioRx, a national specialty pharmacy and infusion services provider, has received limited distribution rights from Shire Human Genetic Therapies, Inc., for its new drug, FIRAZYR® (icatibant injection), which received FDA approval on August 25, 2011. As the only FDA-approved self-injectable treatment for hereditary angioedema (HAE), FIRAZYR® offers HAE patients an important new option for treating HAE attacks.

“As a result of this limited distribution agreement, BioRx expands its therapy offering to patients with hereditary angioedema,” said Phil Rielly, CEO and co-founder of BioRx. “Physicians and patients have been eagerly awaiting the launch of FIRAZYR®, so we are proud to be a part of its introduction to the U.S. market.” FIRAZYR® is now approved in 38 countries worldwide.

HAE is a rare, potentially life-threatening genetic condition that causes episodes of swelling (edema) and fluid retention in various body parts, including the hands, feet, face and airway. Attacks that involve the face and larynx can result in airway closure, asphyxiation and, if untreated, death. An estimated 6,000 to 10,000 people in the United States have HAE.

Shire has begun manufacturing FIRAZYR® and is ready to distribute product to participating pharmacies, including BioRx. The drug comes packaged as a liquid, pre-filled syringe that can be stored at room temperature, offering novel portability for treating unpredictable HAE attacks.

“I’m happy to see FIRAZYR® receive FDA approval, and very pleased to know BioRx will be an approved distributor,” said Timothy J. Craig, D.O. of Penn State Milton S. Hershey Medical Center. “The addition of FIRAZYR® to their capabilities will give treating physicians a valuable, ongoing partner in patient care.”

In addition to FIRAZYR®, BioRx is a distributor of BERINERT® (C1 esterase inhibitor, human), the only FDA-approved C1 esterase inhibitor indicated for acute HAE attacks. BioRx initially entered the HAE market in 2009 with the launch of BERINERT®, manufactured by CSL Behring. Since then, BioRx has quickly become one of the largest providers of HAE treatment in the United States. To learn more about BioRx and its products and services, visit www.biorx.com. ■

About Symmetric Capital

Symmetric Capital, a private equity firm focused on profitable growth companies in the United States and Canada, invested in BioRx in 2010. With the flexibility to invest in either minority or majority ownership positions, Symmetric structures transactions that meet both the immediate and the longer-term objectives of owners and managers – all without changing a company’s entrepreneurial culture or introducing excessive debt that restricts growth. Since 1990, Symmetric’s principals have built dozens of successful, collaborative partnerships, beginning in each case with an equity investment to fund growth, shareholder liquidity, debt repayment, a management-led buyout or a strategic acquisition.

Symmetric targets companies with at least \$10 million in revenues and \$2 million in operating profits. Sectors of interest include business and financial services, healthcare, technology, software, education, and consumer and industrial products. With over \$200 million in committed capital under management, Symmetric typically invests \$5-25 million in each company. Larger transactions can be funded in conjunction with our limited partners or with other co-investors. For more information on Symmetric, please visit www.symmetriccapital.com.